Simple viral/minimal piggyBac hybrid vectors for stable production of self-inactivating gamma-retroviruses
© Troyanovsky et al. 2015
Received: 21 October 2014
Accepted: 17 August 2015
Published: 27 August 2015
Transient production of gamma-retroviruses, including self-inactivating (SIN) retroviruses, is a common method for rapidly generating virus capable of gene delivery. Stable (continuous) production of virus is preferable to transient production for clinical and biotechnology purposes, however, because it allows for significant quantities of a uniform virus to be generated over a prolonged period of time, thus allowing for longitudinal functional studies and quality analysis. Unfortunately, stable production of SIN retroviruses is difficult to achieve.
We describe a novel method to rapidly and cost-effectively create packaging cells capable of continuously producing self-inactivating gamma-retroviruses. We imbedded the SIN proviral construct into a minimal piggyBac transposon vector and then integrated the hybrid vector into packaging cells that already stably expressed the viral gag-pro-pol and envelope genes. Cells that stably produced self-inactivating gamma-retroviruses could be identified (and purified) as early as 3 weeks after initial transfection; these cells produced virus for at least 9 weeks without a decline in titer.
This viral-minimal piggyBac hybrid vector allowed for the rapid generation and purification of packaging cells capable of stably producing self-inactivated gamma-retroviruses. This method can be applied to the large-scale production of viruses for use in research, biotechnology, and potentially, clinical trials.
KeywordsMinimal piggyBac vector Self-inactivating retroviral vector Stable gamma-retroviral production
Gamma-retroviral vectors were first used in gene therapy clinical trials in 1990 [1–4] and remain an important method for stably introducing genes into cells. While viral production can be accomplished more quickly by the short-term (transient) transfer of plasmids [5, 6], continuous stable production of virus is highly desirable for clinical and biotechnology purposes . Stable production allows for the large-scale generation of a uniform virus, facilitating its full characterization. It also reduces the labor involved in repeatedly transfecting packaging cells to obtain virus .
The use of wild type vectors, in which the viral core is integrated into the packaging cell during the initial infection , is an easy method for generating stable gamma-retroviral producing cells. Unfortunately, wild type vectors are more prone to insertional oncogenesis and cell immortalization than self-inactivated (SIN) vectors [8–13] reducing enthusiasm for their use. In addition to a better safety profile, SIN vectors also eliminate internal promoter interference which allows for improved transgene expression . This makes them a better choice than wild type vectors for generating stable virus-producing cells. The absence of an enhancer in both long terminal repeats (LTR) of SIN retroviruses significantly attenuates virus production in packaging cell lines after they are integrated, however . Therefore, while creating stable SIN retroviral-producing cells is possible, it is tedious and time-consuming .
Recently we developed a modified piggyBac transposon delivery system in which the transposase gene and most of both terminal domains were relocated from the delivery cassette into the helper (non-integrating) part of the same plasmid without a significant loss of transposition efficiency . Similar to classical piggyBac vectors, these truncated (minimal) transposon vectors can deliver a large amount of transgenic DNA, yet incorporate significantly less helper DNA (fewer than 100 base pairs) than classical piggyBac vectors or retroviruses. In addition, this minimal piggyBac system has the advantage of requiring only a single-plasmid for delivery. This manuscript describes the practical application of this minimal piggyBac vector system for the large-scale manufacture of clinical-grade, self-inactivating gamma-retroviral vectors. We used this minimal piggyBac delivery system to efficiently integrate SIN retroviral sequences and genes necessary for cell selection such as antibiotic resistance or fluorescent markers into packaging cells. By incorporating a selection marker within the integrated transposon, but outside the gamma-retroviral sequence, we were able to rapidly select only the cells that had integrated the entire provirus and thus, able to stably produce SIN virus.
Phoenix (HEK293 backbone) amphotropic packaging cells were purchased from Orbigen, Inc. (San Diego, CA). They were used for transfection and infection experiments as virus producer and target cells. Cells were cultured in DMEM, 10 % FBS, 2 mmol l-Glutamine and routinely passaged after reaching 80 % confluency. All cells were grown in humidified incubators at 37 °C in 5 % CO2 and harvested by 0.05 % trypsin/0.53 mM EDTA digestion and counted with Coulter Z1 (Coulter Electronics). Counts were made in triplicate.
RNAi-Ready pSIREN-RetroQ-ZsGreen Vector was purchased from ClonTech (Mountain View, CA). It is a self-inactivating (SIN) retroviral expression vector due to a truncation in the 3′ LTR enhancer/promoter region (U3). The hybrid 5′ LTR consists of the cytomegalovirus (CMV) type I enhancer and the mouse sarcoma virus (MSV) promoter. A BglII-BamHI deletion of the U6 promoter and ligation of the vectors ends with a linker to recover EcoRI site generated plasmid B. We then replaced the truncated U3 fragment of the 3′LTR in plasmid B (XhoI-SacI restriction sites fragment) with a full-length U3 part of the 3′LTR from the retroviral vector pBMN-GFP (BsrGI-SacI fragment) (purchased from Orbigen, San Diego, CA) to generate plasmid A. This transformed the SIN 3′LTR in retroviral plasmid B into a wild type 3′LTR, while preserving all other viral sequences including the hybrid CMV/MSV/5′LTR, packaging sequence (Ψ) and the CMV driven ZsGreen identical to those in plasmid B. An SspI-EcoRI deletion in plasmid B generated control plasmid D.
Data are expressed as mean ± SE. Changes in percentage of ZsGreen, turboRFP or ZsGreen/turboRFP-expressing cells, and virus titer were compared using ANOVA combined with Fisher post hoc analysis, with a P value <0.05 considered significant.
Results and discussion
We used minimal piggyBac transposon vectors to efficiently deliver a SIN gamma-retroviral core into the packaging cell genome to allow for stable virus production. To begin, we constructed three gamma-retroviral plasmids each containing the fluorescent marker, ZsGreen, under control of the CMV promoter (Fig. 1): plasmid A was a wild type retrovirus with an intact 3′ LTR; plasmid B was a SIN retrovirus (with a truncated 3′LTR); and plasmid C was a hybrid minimal piggyBac/SIN-retroviral vector that included the entire SIN proviral construct (identical to Plasmid B) and also contained turboRFP as a transposon reporter. Plasmid D lacked both the 5′ LTR and the retroviral packaging sequence and thus was unable to generate virus; it was used as a negative control. Cell density and medium volumes in all experiments were kept similar to allow us to calculate variations in viral titer for each of the vectors.
The initial transfection efficiency of all three retroviral (A–C) and control (D) plasmids in Phoenix amphotropic packaging cells (Orbigen, San Diego, CA), as determined by the percentage of ZsGreen positive cells (or ZsGreen/turboRFP positive cells for plasmid C) 48 h after transfection, was similar (approximately 84 %; Fig. 2a); the fact that plasmid C was 2kB larger than the other plasmids had no effect on transfection efficiency. Conditioned medium was collected from these transfected cells at 3 days and then applied to other amphotropic packaging cells to determine their viral titer (1st infection cycle). Conditioned medium from cells that had integrated virus after the 1st infection cycle (as determined by ZsGreen positivity after infection) was collected and applied to other amphotropic packaging cells to determine their viral titer during a 2nd infection cycle. This experimental design allowed us to determine if virus infectivity could be maintained through both infection cycles.
Conditioned medium harvested 3 days after transfection with the three retroviral plasmids (A–C) demonstrated an equivalent viral titer (Fig. 2b); cells transfected with plasmid D did not make virus and therefore were not analyzed further. As expected, only conditioned medium collected from cells infected with the wild type virus (virus A) was able to infect cells during a 2nd infection cycle with the same efficiency as that of the parental cells (Fig. 2c, A). We did observe a low-level production of retrovirus in cells infected with the SIN virus in the 2nd infection cycle, however (Fig. 2c, B, C). This was most likely due to reactivation of the 5′ LTR(SIN) promoter in some cells as previously suggested by other investigators .
Our goal was to create packaging cells capable of stably generating SIN gamma retroviruses, however. This required the integration of the SIN provirus into the packaging cell genome without losing its ability to produce infectious viral particles. To determine whether an integrated SIN provirus could stably produce virus, we examined viral titers of conditioned media 3 weeks after the initial transfection. We chose this time-point because we have previously demonstrated  that HEK293 cells either integrated or eliminated the minimal piggyBac constructs within 3 weeks of transfection. Therefore, transfected cells that continued to express ZsGreen at 21 days were assumed to have incorporated the viral construct. 10.1 % of cells transfected with plasmid A (wild type) and 2.3 % transfected with plasmid B (SIN) were ZsGreen positive at 21 days. The higher percentage of ZsGreen cells in wild type-infected cells was likely due to the continued infection of cells by the integrated wild type provirus which was capable of making active virus. In contrast, the integrated SIN provirus was not capable of generating infectious particles, so there was minimal cross infection in culture leading to fewer ZsGreen-positive cells. Cells transfected with plasmid C generated two different populations of cells at 21 days: population C’ (ZsGreen-only positive indicating cells that had integrated only the retrovirus during the 21 days, likely through cross infection) and population C (both ZsGreen and turboRFP positive indicating cells in which the entire transposon, with the imbedded retrovirus, had been integrated into the cell). Cells expressing these fluorescent markers 21 days after transfection (Fig. 3a) were purified by flow cytometry and studied further. This gave a total of four sub-populations of cells (A, B, C, and C’).
Wild type (WT) and self-inactivated (SIN) virus production by the used vectors
We used separate reporter markers for the viral and the non-viral parts of the transposon (hybrid) vector. This significantly improved our ability to distinguish between cells that had incorporated the entire hybrid minimal piggyBac/SIN gamma-retroviral construct (and were thus capable of generating infectious SIN gamma-retrovirus) from those that had only integrated the retrovirus (and thus unable to generate infectious SIN gamma retrovirus). Integration of transposons, like integration of retroviruses, is a random event, however. Therefore, even within the population of cells that had integrated the entire piggyBac/SIN gamma-retroviral construct, the site of integration was not likely to be the same in each cell. Over time this could lead to variable virus production if certain cells overgrew the population. To determine whether this occurred in these cells, we randomly generated six individual clones that expressed both fluorescent markers (ZsGreen and TurboRFP) 21 days after transfection and expanded them in culture. Eighty-four days after transfection, all of the six clones produced virus with a similar titer to that from a non-clonal cell population also cultured for total of 84 days (after transfection) (Fig. 4b). This result suggests that in mixed (non-clonal) infected populations of packaging cells, the majority of cells make virus at comparable rates; thus, cloning of infected cells is not required, reducing the cost and time of generating these packaging cells.
In these experiments we used the same cells for both virus production and targeting which allowed us to compare the first (transient) and second (stable) cycles of virus infectivity. However, in packaging cells that already stably express viral GAG-POL and envelope proteins, re-infection occurs with a lower efficiency . This likely explains the lower viral titer in these cells compared to HEK293 cells without these viral proteins. Yet, despite this inhibition, the viral titers obtained are comparable to those used in the manufacturing of clinical-grade SIN gamma-retroviral vectors [6, 19]. The infectivity of gamma-retroviruses depends on the susceptibility of specific target cells to infection and also can be affected by other enhancing technologies [20, 21]. The methods described in this manuscript technique are relevant only to gamma-retroviral vectors since the continuous expression of the lentiviral GAG-PRO is known to be toxic to packaging cells .
Minimal piggyBac vectors  can incorporate DNA sequences up to (at least) 15 Kb into cells (unpublished data) allowing the stable delivery of large retroviral sequences. Using this vector to deliver the SIN retroviral construct increased the efficiency of proviral DNA incorporation into virus producing cells more than 30-times compared with the use of non-transposon stable plasmid delivery systems [from 0.3 ± 0.1 (ZsGreen positive cells, plasmid D) to 9.1 ± 1.1 % (ZsGreen/RFP double positive cells, plasmid C); Fig. 3a]. Usual piggyBac vectors can also be used for gamma-retroviral delivery . Two important advantages of using a minimal rather than a classical piggyBac vector, however, are that the minimal vector is a single plasmid system which allows for more efficient delivery and that transposons integrated into cells remain non-removable even in the presence of transposase. Thus, minimal piggyBac vector can be used repeatedly for multiple integration events without the risk of losing previously integrated fragments. No additional components, such as helper plasmids, proteins or mRNAs (commonly used with traditional transposon systems) are needed. The proposed system provides a continuously-producing, highly-consistent cell system that can be used to generate SIN retroviral vectors that meet the standard for current Good Manufacturing Practices [1, 2, 24].
VB, BF and VS conceived the idea and designed the experiments. BT and VS performed the experiments and the statistical analysis. BF and VS wrote the manuscript and interpreted the data. All authors read and approved the final manuscript.
This work was supported in part by a STTR (R41) Grant from the National Institutes of Health to V.S. (1R41GM109527-01) and a Grant-in-Aid award from the Greater SouthEast Affiliate of the American Heart Association to V.S. (12GRNT12070291).
Compliance with ethical guidelines
Competing interests The authors declare no competing financial interests.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Coroadinha AS, Gama-Norton L, Amaral AI, Hauser H, Alves PM, Cruz PE. Production of retroviral vectors: review. Curr Gene Ther. 2010;10:456–73.View ArticlePubMedGoogle Scholar
- Eckert HG, Kuhlcke K, Schilz AJ, Lindemann C, Basara N, Fauser AA, Baum C. Clinical scale production of an improved retroviral vector expressing the human multidrug resistance 1 gene (MDR1). Bone Marrow Transplant. 2000;25(Suppl 2):S114–7.View ArticlePubMedGoogle Scholar
- Danos O, Mulligan RC. Safe and efficient generation of recombinant retroviruses with amphotropic and ecotropic host ranges. Proc Natl Acad Sci USA. 1988;85:6460–4.PubMed CentralView ArticlePubMedGoogle Scholar
- Markowitz DG, Goff SP, Bank A. Safe and efficient ecotropic and amphotropic packaging lines for use in gene transfer experiments. Trans Assoc Am Phys. 1988;101:212–8.PubMedGoogle Scholar
- Cornetta K, Pollok KE, Miller AD. Retroviral vector production by transient transfection. CSH Protoc 2008, 2008:pdb prot4881.Google Scholar
- van der Loo JC, Swaney WP, Grassman E, Terwilliger A, Higashimoto T, Schambach A, Baum C, Thrasher AJ, Williams DA, Nordling DL, et al. Scale-up and manufacturing of clinical-grade self-inactivating gamma-retroviral vectors by transient transfection. Gene Ther. 2012;19:246–54.PubMed CentralView ArticlePubMedGoogle Scholar
- Cornetta K, Pollok KE, Miller AD. Generation of stable vector-producing cells for retroviral vectors. CSH Protoc 2008, 2008:pdb prot4882.Google Scholar
- Cavazza A, Cocchiarella F, Bartholomae C, Schmidt M, Pincelli C, Larcher F, Mavilio F. Self-inactivating MLV vectors have a reduced genotoxic profile in human epidermal keratinocytes. Gene Ther. 2013;20:949–57.View ArticlePubMedGoogle Scholar
- Romano G. Development of safer gene delivery systems to minimize the risk of insertional mutagenesis-related malignancies: a critical issue for the field of gene therapy. ISRN Oncol. 2012;2012:616310.PubMed CentralPubMedGoogle Scholar
- Hacein-Bey-Abina S, Garrigue A, Wang GP, Soulier J, Lim A, Morillon E, Clappier E, Caccavelli L, Delabesse E, Beldjord K, et al. Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J Clin Invest. 2008;118:3132–42.PubMed CentralView ArticlePubMedGoogle Scholar
- Maruggi G, Porcellini S, Facchini G, Perna SK, Cattoglio C, Sartori D, Ambrosi A, Schambach A, Baum C, Bonini C, et al. Transcriptional enhancers induce insertional gene deregulation independently from the vector type and design. Mol Ther. 2009;17:851–6.PubMed CentralView ArticlePubMedGoogle Scholar
- Modlich U, Navarro S, Zychlinski D, Maetzig T, Knoess S, Brugman MH, Schambach A, Charrier S, Galy A, Thrasher AJ, et al. Insertional transformation of hematopoietic cells by self-inactivating lentiviral and gammaretroviral vectors. Mol Ther. 2009;17:1919–28.PubMed CentralView ArticlePubMedGoogle Scholar
- Hacein-Bey-Abina S, Pai SY, Gaspar HB, Armant M, Berry CC, Blanche S, Bleesing J, Blondeau J, de Boer H, Buckland KF, et al. A modified gamma-retrovirus vector for X-linked severe combined immunodeficiency. N Engl J Med. 2014;371:1407–17.PubMed CentralView ArticlePubMedGoogle Scholar
- Yee JK, Moores JC, Jolly DJ, Wolff JA, Respess JG, Friedmann T. Gene expression from transcriptionally disabled retroviral vectors. Proc Natl Acad Sci USA. 1987;84:5197–201.PubMed CentralView ArticlePubMedGoogle Scholar
- Maetzig T, Galla M, Baum C, Schambach A. Gammaretroviral vectors: biology, technology and application. Viruses. 2011;3:677–713.PubMed CentralView ArticlePubMedGoogle Scholar
- Loew R, Meyer Y, Kuehlcke K, Gama-Norton L, Wirth D, Hauser H, Stein S, Grez M, Thornhill S, Thrasher A, et al. A new PG13-based packaging cell line for stable production of clinical-grade self-inactivating gamma-retroviral vectors using targeted integration. Gene Ther. 2010;17:272–80.View ArticlePubMedGoogle Scholar
- Solodushko V, Bitko V, Fouty B. Minimal piggyBac vectors for chromatin integration. Gene Ther. 2014;21:1–9.View ArticlePubMedGoogle Scholar
- Xu W, Russ JL, Eiden MV. Evaluation of residual promoter activity in gamma-retroviral self-inactivating (SIN) vectors. Mol Ther. 2012;20:84–90.PubMed CentralView ArticlePubMedGoogle Scholar
- van der Loo JC, Swaney WP, Grassman E, Terwilliger A, Higashimoto T, Schambach A, Hacein-Bey-Abina S, Nordling DL, Cavazzana-Calvo M, Thrasher AJ, et al. Critical variables affecting clinical-grade production of the self-inactivating gamma-retroviral vector for the treatment of X-linked severe combined immunodeficiency. Gene Ther. 2012;19:872–6.PubMed CentralView ArticlePubMedGoogle Scholar
- Solodushko V, Bitko V, Fouty B. Dexamethasone and mifepristone increase retroviral infectivity through different mechanisms. Am J Physiol Lung Cell Mol Physiol. 2009;297:L538–45.PubMed CentralView ArticlePubMedGoogle Scholar
- Solodushko V, Fouty B. Mifepristone increases gamma-retroviral infection efficiency by enhancing the integration of virus into the genome of infected cells. Gene Ther. 2010;17:1253–61.PubMed CentralView ArticlePubMedGoogle Scholar
- Matrai J, Chuah MK, VandenDriessche T. Recent advances in lentiviral vector development and applications. Mol Ther. 2010;18:477–90.PubMed CentralView ArticlePubMedGoogle Scholar
- Feldman SA, Xu H, Black MA, Park TS, Robbins PF, Kochenderfer JN, Morgan RA, Rosenberg SA. Use of the piggyBac transposon to create stable packaging cell lines for the production of clinical-grade self-inactivating gamma-retroviral vectors. Hum Gene Ther Methods. 2014;25:253–60.PubMed CentralView ArticlePubMedGoogle Scholar
- Merten OW. State-of-the-art of the production of retroviral vectors. J Gene Med. 2004;6(Suppl 1):S105–24.View ArticlePubMedGoogle Scholar